IL-15 and IL-15R\alpha sushi domain based immunocytokines

Patent metadata

Field	Value
Publication number	US-10626155-B2
Application number	US-201615214032-A
Country	US
Kind code	B2
Filing date	Jul 19, 2016
Priority date	Jun 24, 2011
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15Rα) or derivatives thereof; and uses thereof.

First claim

We claim:

1. An immunocytokine comprising:
a) a conjugate, and
b) an antibody or a fragment thereof, wherein said fragment thereof is capable of reacting with the same antigen as its antibody counterpart, directly or indirectly linked by covalence to said conjugate,
wherein said conjugate comprises:
(i) a polypeptide comprising the amino acid sequence of an interleukin 15, and
(ii) a polypeptide comprising the amino acid sequence of a sushi domain of an interleukin-15 receptor alpha (IL-15Rα)

wherein the conjugate comprises the amino acid sequence of SEQ ID NO: 17.

2. The immunocytokine of claim 1 , wherein the amino acid sequence of the conjugate and the amino acid sequence of the antibody or fragment thereof are not separated by any linker amino acid sequence.

3. The immunocytokine of claim 1 , wherein the amino acid sequence of the conjugate and the amino acid sequence of the antibody or fragment thereof are separated by a linker amino acid sequence.

4. The immunocytokine of claim 1 , wherein the antibody or fragment thereof is directed against an antigen selected from the group consisting of tumor neovascularization antigens and tumor extracellular matrix antigens.

5. The immunocytokine of claim 1 , wherein the amino acid sequence of the conjugate is in a C-terminal position relative to the amino acid sequence of the antibody or fragment thereof.

6. The immunocytokine of claim 1 , wherein the antibody or fragment thereof is directed against tumoral antigens.

7. A pharmaceutical composition comprising the immunocytokine as defined in claim 1 , and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , wherein said pharmaceutical composition is for treating cancer in a subject by an administration by injection at a dose of 2.5 mg/kg of subject or less.

Assignees

• Cytune Pharma
• Inst Nat Sante Rech Med

Inventors

• Morisseau Sebastien Daniel
• Teppaz Geraldine
• Jacques Yannick Laurent Joseph
• Robert Bruno Gilbert Marc
• De Martynoff Guy Luc Michel
• Bechard David

Classifications

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title

• C07K14/5443 Primary

  IL-15 · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title